Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1965) 1965
Publication (144) 144
Book Review (26) 26
Book Chapter (25) 25
Newsletter (15) 15
Book / eBook (11) 11
Conference Proceeding (3) 3
Dissertation (2) 2
Magazine Article (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (1014) 1014
humans (875) 875
index medicus (791) 791
male (718) 718
rats (513) 513
hypertension (465) 465
angiotensin (448) 448
female (428) 428
blood pressure - drug effects (402) 402
renin - antagonists & inhibitors (398) 398
amides - pharmacology (338) 338
fumarates - therapeutic use (317) 317
pharmacology & pharmacy (315) 315
amides - therapeutic use (314) 314
aliskiren (300) 300
fumarates - pharmacology (288) 288
angiotensin ii - pharmacology (281) 281
angiotensin-ii (276) 276
hypertension - drug therapy (276) 276
renin-angiotensin system - drug effects (261) 261
angiotensin ii (242) 242
antihypertensive agents - therapeutic use (241) 241
blood-pressure (236) 236
peripheral vascular disease (225) 225
renin-angiotensin system (206) 206
renin (198) 198
middle aged (195) 195
blood pressure (188) 188
biochemistry & molecular biology (176) 176
physiology (172) 172
antihypertensive agents - pharmacology (168) 168
angiotensin-converting enzyme (166) 166
adult (159) 159
mice (157) 157
aged (151) 151
analysis (149) 149
renin - blood (145) 145
drug therapy, combination (144) 144
rats, sprague-dawley (142) 142
hypertension - physiopathology (141) 141
enzymes (138) 138
dose-response relationship, drug (132) 132
fumarates - administration & dosage (126) 126
amides - administration & dosage (124) 124
cardiac & cardiovascular systems (124) 124
treatment outcome (120) 120
fumarates - adverse effects (116) 116
peptides (116) 116
angiotensin-converting enzyme inhibitors - pharmacology (115) 115
expression (112) 112
oxidative stress (111) 111
amides - adverse effects (109) 109
endocrinology & metabolism (105) 105
physiological aspects (105) 105
urology & nephrology (105) 105
angiotensin-converting enzyme inhibitors - therapeutic use (102) 102
antihypertensive agents - adverse effects (102) 102
angiotensin ii - metabolism (100) 100
proteins (100) 100
research (100) 100
valsartan (99) 99
angiotensin amide - pharmacology (96) 96
time factors (96) 96
in vitro techniques (95) 95
receptor (95) 95
rats, wistar (94) 94
rabbits (91) 91
norepinephrine - pharmacology (90) 90
renin - metabolism (90) 90
medicine (89) 89
disease models, animal (87) 87
antihypertensive agents - administration & dosage (86) 86
drug therapy (85) 85
heart-failure (85) 85
renin-angiotensin system - physiology (85) 85
chemistry, medicinal (84) 84
diabetes (80) 80
inhibition (80) 80
activation (77) 77
dogs (77) 77
kidney - drug effects (77) 77
angiotensins (76) 76
system (76) 76
angiotensin ii type 1 receptor blockers - pharmacology (73) 73
cells, cultured (73) 73
renin inhibitor (73) 73
ace inhibitors (72) 72
antihypertensive efficacy (72) 72
kidney (72) 72
structure-activity relationship (72) 72
health aspects (70) 70
medicine & public health (68) 68
pharmacology (67) 67
amino acid sequence (66) 66
angiotensin ii - blood (66) 66
mice, inbred c57bl (66) 66
article (65) 65
enzyme inhibitors - pharmacology (65) 65
rodents (63) 63
combination (61) 61
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1948) 1948
German (26) 26
Russian (13) 13
Italian (8) 8
French (5) 5
Spanish (3) 3
Turkish (3) 3
Czech (2) 2
Chinese (1) 1
Hebrew (1) 1
Hungarian (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans
by Fisher, Naomi and Danser, Jan and Nussberger, Jürgen and Dole, William and Hollenberg, Norman
Circulation (Baltimore), ISSN 0009-7322, 06/2008, Volume 117, Issue 25, pp. 3199 - 3205
textabstractBackground - Pharmacological interruption of the renin-angiotensin system focuses on optimization of blockade. As a measure of intrarenal renin... 
Drugs | Hypertension | Renin | Kidney | Angiotensin | SYSTEM | DEPENDENT DIABETES-MELLITUS | PLASMA PRORENIN | ACTIVE RENIN | CARDIAC & CARDIOVASCULAR SYSTEMS | NONPROTEOLYTIC ACTIVATION | drugs | CONVERTING-ENZYME-INHIBITION | ANGIOTENSIN-II | MONOCLONAL-ANTIBODY | kidney | renin | angiotensin | PERIPHERAL VASCULAR DISEASE | ESSENTIAL-HYPERTENSION | (PRO)RENIN RECEPTOR | HEMATOLOGY | hypertension | Predictive Value of Tests | Sodium, Dietary | Antihypertensive Agents - pharmacology | Captopril - pharmacology | Humans | Middle Aged | Angiotensin II - blood | Angiotensin I - drug effects | Antihypertensive Agents - administration & dosage | Renal Circulation - physiology | Renal Plasma Flow - drug effects | Fumarates - administration & dosage | Male | Reference Values | Renal Plasma Flow - physiology | Dose-Response Relationship, Drug | Glomerular Filtration Rate - drug effects | Sodium - urine | Adult | Female | Renal Circulation - drug effects | Blood Pressure - drug effects | Blood Pressure - physiology | Amides - pharmacology | Angiotensin II - drug effects | Natriuresis - drug effects | Administration, Oral | Amides - blood | Angiotensin I - blood | Renin - blood | Antihypertensive Agents - blood | Captopril - administration & dosage | Fumarates - blood | Renin - antagonists & inhibitors | Diet | Fumarates - pharmacology | Vasodilation - drug effects | Amides - administration & dosage | Physiological aspects | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text The granin VGF promotes genesis of secretory vesicles, and regulates circulating catecholamine levels and blood pressure
by Fargali, Samira and Garcia, Angelo L and Sadahiro, Masato and Jiang, Cheng and Janssen, William G and Lin, Wei-Jye and Cogliani, Valeria and Elste, Alice and Mortillo, Steven and Cero, Cheryl and Veitenheimer, Britta and Graiani, Gallia and Pasinetti, Giulio M and Mahata, Sushil K and Osborn, John W and Huntley, George W and Phillips, Greg R and Benson, Deanna L and Bartolomucci, Alessandro and Salton, Stephen R
FASEB Journal, ISSN 0892-6638, 2014, Volume 28, Issue 5, pp. 2120 - 2133
Secretion of proteins and neurotransmitters from large dense core vesicles (LDCVs) is a highly regulated process. Adrenal LDCV formation involves the granin... 
Large dense core vesicle | LDCV | Norepinephrine | Chromaffin granule | Adrenal | norepinephrine | ENDOCRINE TISSUES | BIOCHEMISTRY & MOLECULAR BIOLOGY | GRANULE-LIKE STRUCTURES | TARGETED ABLATION | CHROMOGRANIN-A | NERVE GROWTH-FACTOR | NEUROPEPTIDE-Y | CELL BIOLOGY | chromaffin granule | NEUROENDOCRINE PROTEIN VGF | ENERGY-EXPENDITURE | adrenal | MESSENGER-RNA | BIOLOGY | DENSE-CORE GRANULES | large dense core vesicle | Blood Pressure | Adrenal Medulla - metabolism | NIH 3T3 Cells | Peptide Fragments - metabolism | Angiotensin Amide - blood | Humans | Mice, Inbred C57BL | Neurotransmitter Agents - metabolism | Secretory Vesicles - metabolism | Cytoplasm - metabolism | Neuropeptides - metabolism | Gene Knock-In Techniques | Mice, Knockout | Chromaffin Cells - metabolism | Phenotype | Animals | Epinephrine - blood | Chromogranin A - metabolism | Mice | Neuropeptides - genetics | Research Communications
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers
by Felix Waldmeier and Ulrike Glaenzel and Bernard Wirz and Lukas Oberer and Dietmar Schmid and Michael Seiberling and Jessica Valencia and Gilles-Jacques Riviere and Peter End and Sujata Vaidyanathan
Drug Metabolism and Disposition, ISSN 0090-9556, 08/2007, Volume 35, Issue 8, pp. 1418 - 1428
Aliskiren (2( S ),4( S ),5( S ),7( S )- N -(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamid... 
ANGIOTENSIN SYSTEM | PLASMA | PHARMACOKINETICS | EFFICACY | TOLERABILITY | DRUGS | PHARMACOLOGY & PHARMACY | PHARMACODYNAMICS | HYPERTENSION | Area Under Curve | Humans | Middle Aged | Urine - chemistry | Antihypertensive Agents - urine | Amides - blood | Male | Antihypertensive Agents - metabolism | Antihypertensive Agents - pharmacokinetics | Intestinal Absorption | Tissue Distribution | Feces - chemistry | Fumarates - blood | Renin - antagonists & inhibitors | Spectrometry, Mass, Electrospray Ionization | Fumarates - pharmacokinetics | Biotransformation | Amides - pharmacokinetics | Fumarates - metabolism | Adult | Amides - metabolism | Molecular Structure
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin
by Lange, Sascha and Fraune, Christoph and Alenina, Natalia and Bader, Michael and Danser, A. H. Jan and Frenay, Anne-Roos and van Goor, Harry and Stahl, Rolf and Nguyen, Genevieve and Schwedhelm, Edzard and Wenzel, Ulrich Otto
Journal of Hypertension, ISSN 0263-6352, 04/2013, Volume 31, Issue 4, pp. 713 - 719
Background and objective: The antihypertensive effects of the direct renin inhibitor aliskiren last substantially longer after treatment withdrawal than... 
aliskiren | RATS | INCREASES | ANGIOTENSIN-II | PROSEGMENT | BLOOD-PRESSURE | kidney | INHIBITION | renin | DOUBLE-BLIND | MICE | handle region peptide | BLOCKADE | (pro)renin receptor | ARB | ACE | RAS | angiotensin | (P)RR | angiotensin receptor blocker | Ang | angiotensin II type 1 receptor | AT1a receptor | renin-angiotensin system | angiotensin-converting enzyme | PERIPHERAL VASCULAR DISEASE | Immunohistochemistry | Renin - metabolism | Humans | Mice, Inbred C57BL | Amides - blood | Antihypertensive Agents - metabolism | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - blood | Mice, Knockout | Kidney - metabolism | Animals | Fumarates - blood | Fumarates - pharmacokinetics | Amides - pharmacokinetics | Fumarates - metabolism | Protein Binding | Amides - metabolism | Mice
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Reversibility of the Effects of Aliskiren in the Renal Versus Systemic Circulation
by Markus P. Schneider and Rolf Janka and Thomas Ziegler and Ulrike Raff and Martin Ritt and Christian Ott and Roland Veelken and Michael Uder and Roland E. Schmieder
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 02/2012, Volume 7, Issue 2, pp. 258 - 264
Background and objectives Renal hemodynamic effects of inhibitors of the renin-angiotensin system can increase the risk of acute kidney injury under certain... 
KIDNEYS | THERAPY | RAMIPRIL | SAFETY | RENIN INHIBITOR ALISKIREN | ANTIHYPERTENSIVE EFFICACY | HUMANS | UROLOGY & NEPHROLOGY | PERFUSION | HYPERTENSION | BLOOD-PRESSURE | Vasodilator Agents - pharmacokinetics | Vasodilator Agents - therapeutic use | Humans | Middle Aged | Angiotensin II - blood | Half-Life | Hypertension - drug therapy | Male | Hypertension - blood | Time Factors | Amides - pharmacokinetics | Adult | Female | Renal Circulation - drug effects | Blood Pressure - drug effects | Fumarates - therapeutic use | Perfusion Imaging - methods | Aldosterone - blood | Amides - blood | Treatment Outcome | Amides - therapeutic use | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - therapeutic use | Renin - blood | Hypertension - physiopathology | Antihypertensive Agents - blood | Vasodilator Agents - blood | Magnetic Resonance Imaging | Fumarates - blood | Renin - antagonists & inhibitors | Analysis of Variance | Fumarates - pharmacokinetics | Renin-Angiotensin System - drug effects | Aged | Vasodilation - drug effects | Germany | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Influence of Body Weight and Gender on the Pharmacokinetics, Pharmacodynamics, and Antihypertensive Efficacy of Aliskiren
by Jarugula, Venkateswar and Yeh, Ching‐Ming and Howard, Dan and Bush, Christopher and Keefe, Deborah L and Dole, William P
The Journal of Clinical Pharmacology, ISSN 0091-2700, 12/2010, Volume 50, Issue 12, pp. 1358 - 1366
Gender and body weight influence the pharmacokinetics and pharmacodynamics of many drugs. This pooled analysis of 17 clinical studies evaluated the effect of... 
body weight | direct renin inhibitor | pharmacokinetics | Blood pressure | renin‐angiotensin system | renin-angiotensin system | HEALTHY-SUBJECTS | EXHIBITS SIMILAR PHARMACOKINETICS | COMBINATION | BLOOD-PRESSURE | HYDROCHLOROTHIAZIDE | OBESE-PATIENTS | DOSE-DEPENDENT EFFICACY | PHARMACOLOGY & PHARMACY | HYPERTENSION | PLACEBO-LIKE TOLERABILITY | Body Composition | Antihypertensive Agents - pharmacology | Body Weight | Humans | Hypertension - drug therapy | Male | Hypertension - blood | Amides - pharmacokinetics | Adult | Female | Blood Pressure - drug effects | Amides - pharmacology | Body Mass Index | Fumarates - therapeutic use | Amides - blood | Amides - therapeutic use | Clinical Trials as Topic | Antihypertensive Agents - pharmacokinetics | Sex Characteristics | Antihypertensive Agents - therapeutic use | Renin - blood | Antihypertensive Agents - blood | Fumarates - blood | Renin - antagonists & inhibitors | Fumarates - pharmacokinetics | Fumarates - pharmacology | Body mass index | Research | Pharmacokinetics | Health aspects | Body weight | Hypertension | Plasma | Gender
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pharmacokinetics, Safety, and Tolerability of the Oral Renin Inhibitor Aliskiren in Patients With Hepatic Impairment
by Vaidyanathan, Sujata and Warren, Vance and Yeh, ChingMing and Bizot, Marie‐Noelle and Dieterich, Hans Armin and Dole, William P
The Journal of Clinical Pharmacology, ISSN 0091-2700, 02/2007, Volume 47, Issue 2, pp. 192 - 200
Aliskiren is the first in a new class of orally active, direct renin inhibitors for the treatment of hypertension. This open‐label, nonrandomized,... 
Aliskiren | pharmacokinetics | liver | renin‐angiotensin system | Pharmacokinetics | Reninangiotensin system | Liver | SYSTEM | reninangiotensin system | aliskiren | DISEASE | PHARMACOLOGY & PHARMACY | ANGIOTENSIN-II | PHARMACODYNAMICS | CLINICAL PHARMACOKINETICS | HYPERTENSION | Fumarates - blood | Renin - antagonists & inhibitors | Fumarates - pharmacokinetics | Humans | Amides - adverse effects | Amides - pharmacokinetics | Amides - blood | Antihypertensive Agents - pharmacokinetics | Fumarates - adverse effects | Liver Diseases - metabolism | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Hypertension | Physiological aspects | Liver diseases | Research | Drug therapy | ACE inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects
by Vaidyanathan, Sujata and Jermany, Joanne and Yeh, ChingMing and Bizot, Marie-Noelle and Camisasca, Riccardo
British Journal of Clinical Pharmacology, ISSN 0306-5251, 12/2006, Volume 62, Issue 6, pp. 690 - 698
Aims Aliskiren is the first in a new class of orally effective renin inhibitors for the treatment of hypertension. This study compared the pharmacokinetic and... 
renin inhibitor | aliskiren | hypertension | ethnic differences | Hypertension | Aliskiren | Renin inhibitor | Ethnic differences | ETHNIC-DIFFERENCES | ANGIOTENSIN SYSTEM | GUIDELINES | PLASMA-RENIN | PHARMACOLOGY & PHARMACY | HYPERTENSIVE PATIENTS | Amides - pharmacology | Antihypertensive Agents - pharmacology | European Continental Ancestry Group - genetics | Humans | Middle Aged | Asian Continental Ancestry Group - genetics | Amides - blood | Hypertension - drug therapy | Male | Antihypertensive Agents - pharmacokinetics | Renin - blood | Antihypertensive Agents - blood | Fumarates - blood | Renin - antagonists & inhibitors | Fumarates - pharmacokinetics | Fumarates - pharmacology | Amides - pharmacokinetics | Adult | Renin-Angiotensin System - drug effects | Blood Pressure - drug effects | Pharmacokinetics & Pharmacodynamics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Renal Protective Effects of Aliskiren Beyond Its Antihypertensive Property in a Mouse Model of Progressive Fibrosis
by Gross, Oliver and Girgert, Rainer and Rubel, Diana and Temme, Johanna and Theissen, Stephanie and Müller, Gerhard-Anton
American Journal of Hypertension, ISSN 0895-7061, 03/2011, Volume 24, Issue 3, pp. 355 - 361
Background The direct renin inhibitor aliskiren is known to exhibit a strong antihypertensive effect. However, the organoprotective potential of aliskiren... 
blood pressure | renal insufficiency | Alport syndrome | collagen | renal hypertension | fibrosis | hypertension | SPONTANEOUSLY HYPERTENSIVE-RATS | RECEPTOR | ALPORT-SYNDROME | NEPHROPATHY | ACE-INHIBITORS | RENIN-ANGIOTENSIN SYSTEM | TRANSFORMING GROWTH-FACTOR-BETA-1 | DISEASE | PERIPHERAL VASCULAR DISEASE | ALDOSTERONE | BLOCKADE | Amides - pharmacology | Antihypertensive Agents - pharmacology | Kidney - drug effects | Kidney - pathology | Fumarates - therapeutic use | Amides - blood | Extracellular Matrix - metabolism | Amides - therapeutic use | Connective Tissue Growth Factor - analysis | Connective Tissue Growth Factor - biosynthesis | Autoantigens - physiology | Collagen Type IV - physiology | Animals | Fumarates - blood | Proteinuria - drug therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Collagen Type IV - deficiency | Fumarates - pharmacology | Fibrosis | Mice | Transforming Growth Factor beta1 - analysis | Uremia - prevention & control | Transforming Growth Factor beta1 - biosynthesis | Disease Models, Animal | Prevention | Antihypertensive drugs | Dosage and administration | Kidney diseases | Patient outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Persistent elevation of fibroblast growth factor 23 concentrations in healthy appropriate-for-gestational-age preterm infants
by Fatani, Tarah and Binjab, Asma and Weiler, Hope and Sharma, Atul and Rodd, Celia
Journal of Pediatric Endocrinology and Metabolism, ISSN 0334-018X, 07/2015, Volume 28, Issue 7, pp. 825 - 832
To explore the temporal evolution of 25-hydroxyvitamin D [25(OH)D], its epimer, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and minerals in... 
calcium | FGF23 | vitamin D | phosphorus | premature infant | Vitamin D | VITAMIN-D SUPPLEMENTATION | RICKETS | D DEFICIENCY | PREVENTION | METABOLIC BONE-DISEASE | CHILDREN | PHOSPHATE | GLOMERULAR-FILTRATION-RATE | ACCOUNT | ENDOCRINOLOGY & METABOLISM | FRACTURES | PEDIATRICS | Diabetes, Gestational - blood | Prognosis | Prospective Studies | Follow-Up Studies | Angiotensin Amide - blood | Humans | Male | Biomarkers - blood | Gestational Age | Pre-Eclampsia - physiopathology | Case-Control Studies | Pregnancy | Tandem Mass Spectrometry | Infant, Premature - blood | Fibroblast Growth Factors - blood | Pre-Eclampsia - blood | Diabetes, Gestational - physiopathology | Chromatography, Liquid | Adult | Female | Infant, Newborn | Term Birth | Physiological aspects | Fibroblast growth factors | Infants (Premature) | Abnormalities
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text RENIN INHIBITION WITH ALISKIREN
by Wuerzner, Gregoire and Azizi, Michel
Clinical and Experimental Pharmacology and Physiology, ISSN 0305-1870, 04/2008, Volume 35, Issue 4, pp. 426 - 430
SUMMARY • Initial attempts to inhibit renin in humans have faced numerous difficulties. Molecular modelling and X-ray crystallography of the active site of... 
inhibitor | hypertension | renin | pharmacology | Hypertension | Inhibitor | Pharmacology | Renin | CONVERTING ENZYME-INHIBITOR | PHYSIOLOGY | TRANSGENIC RATS | RECEPTOR | ANGIOTENSIN-II | BLOOD-PRESSURE | ASPARTYL-LYSYL-PROLINE | DIABETES-MELLITUS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | ESSENTIAL-HYPERTENSION | RENAL INJURY | Fumarates - therapeutic use | Humans | Amides - blood | Hypertension - drug therapy | Amides - therapeutic use | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - blood | Dose-Response Relationship, Drug | Clinical Trials, Phase III as Topic | Fumarates - blood | Fumarates - pharmacokinetics | Amides - pharmacokinetics | Blood Pressure - drug effects | Drug Therapy, Combination | Clinical Trials, Phase II as Topic | Amides, blood | Antihypertensive Agents, therapeutic use | Fumarates, blood | Fumarates, pharmacokinetics | Hypertension, drug therapy | Amides, pharmacokinetics | Antihypertensive Agents, pharmacokinetics | Antihypertensive Agents, blood | Fumarates, therapeutic use | Amides, therapeutic use | Blood Pressure, drug effects | Enzyme inhibitors | Peptide hormones | Angiotensin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Mass spectrometric quantification of AcSDKP‐NH2 in human plasma and urine and comparison with an immunoassay
by Mesmin, Cédric and Cholet, Sophie and Blanchard, Anne and Chambon, Yann and Azizi, Michel and Ezan, Eric
Rapid Communications in Mass Spectrometry, ISSN 0951-4198, 01/2012, Volume 26, Issue 2, pp. 163 - 172
RATIONALE Precise assessment of renal glomerular filtration rate (GFR) is essential for the early detection of chronic kidney disease. AcSDKP‐NH2, an analogue... 
CHEMISTRY, ANALYTICAL | BIOCHEMICAL RESEARCH METHODS | RENAL-DISEASE | PRO | INTERFERENCES | ANGIOTENSIN-CONVERTING ENZYME | ASPARTYL-LYSYL-PROLINE | GLOMERULAR-FILTRATION-RATE | PEPTIDES | INHIBITION | SPECTROSCOPY | METHOD VALIDATION | DRUG DEVELOPMENT | Biomarkers - urine | Amides - urine | Humans | Male | Chromatography, High Pressure Liquid | Oligopeptides - urine | Young Adult | Tandem Mass Spectrometry | Amides - pharmacokinetics | Statistics, Nonparametric | Adult | Oligopeptides - chemistry | Limit of Detection | Reproducibility of Results | Glomerular Filtration Rate | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Amides - blood | Linear Models | Biomarkers - blood | Immunoenzyme Techniques - methods | Spectrometry, Mass, Electrospray Ionization - methods | Adolescent | Amides - chemistry | Hydrophobic and Hydrophilic Interactions | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Pharmacokinetic/Pharmacodynamic Modeling of Renin Biomarkers in Subjects Treated With the Renin Inhibitor Aliskiren
by Hong, Y and Dingemanse, J and Mager, DE
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 07/2008, Volume 84, Issue 1, pp. 136 - 143
A semimechanistic pharmacokinetic/pharmacodynamic (PK/PD) model was developed to evaluate the effects of aliskiren on the renin–angiotensin system (RAS) in... 
MEDIATED DRUG DISPOSITION | PHARMACOKINETIC MODEL | ACTIVE RENIN | PLASMA | CONVERTING-ENZYME-INHIBITOR | ANGIOTENSIN-ALDOSTERONE SYSTEM | PHARMACOLOGY & PHARMACY | COMBINATION | BLOOD-PRESSURE | HYPERTENSIVE PATIENTS | RANDOMIZED TRIAL | Amides - pharmacology | Renin - metabolism | Controlled Clinical Trials as Topic - methods | Humans | Amides - blood | Male | Renin-Angiotensin System - physiology | Biomarkers - blood | Renin - blood | Cross-Over Studies | Dose-Response Relationship, Drug | Fumarates - blood | Renin - antagonists & inhibitors | Fumarates - pharmacokinetics | Models, Biological | Fumarates - pharmacology | Amides - pharmacokinetics | Renin-Angiotensin System - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights